Photo of Holly Schepisi
R New Jersey Senate · District 39

Sen. Holly Schepisi

Compare
Total votes
3,765
all sessions
Attendance
80%
462 missed
Lower than 82% of chamber peers
With party
98%
of cast votes
Lower than 80% of chamber peers
Bipartisan score
2%
crosses aisle rarely
Near the chamber average
Sponsored
660
bills & resolutions
Near the chamber average
Committees
2
assignments
3,765 roll-call votes

Voting record

Yea
2,760
voted in favor
Nay
458
voted against
Absent
462
missed votes
Total cast
3,765
across all sessions
Crossed party
60
votes against own party
This page
3,765
matching current filters
Bill
Description
Vote
Result
Tally
Date
A 3862
Permits professional and occupational licensing boards to expedite licensure of certain individuals during state of emergency or public health emergency.
Other
Passed
65–0
Mar 16, 2020
S 908
Clarifies association assessment payment requirements in planned real estate developments.*
Yea
Passed
7–0
Mar 5, 2020
A 2280
Criminalizes certain payments for referral of patients to substance use disorder treatment facilities.*
Yea
Passed
12–0
Mar 5, 2020
A 1079
Requires certain health care professionals to undergo explicit and implicit bias training.* Bipartisan
Yea
Passed
10–2
Mar 5, 2020
A 1635
Permits use of telemedicine and telehealth to authorise patients for medical cannabis and to issue written instructions for dispensing medical cannabis.* Bipartisan
Yea
Passed
10–2
Mar 5, 2020
S 619
Permits use of telemedicine and telehealth to authorize patients for medical cannabis and to issue written instructions for dispensing medical cannabis. * Bipartisan
Yea
Passed
10–2
Mar 5, 2020
A 2480
Clarifies association assessment payment requirements in planned real estate developments.*
Yea
Passed
7–0
Mar 5, 2020
A 2636
Concerns online marketing of affordable housing units.
Yea
Passed
7–0
Mar 5, 2020
AJR 22
Designates March as "Multiple System Atrophy Awareness Month."
Yea
Passed
12–0
Mar 5, 2020
A 277
Requires public members of Drug Utilization Review Board to disclose financial interests and benefits received from and investment interests held in pharmaceutical distributors, pharmaceutical manufacturers, or pharmacy benefits managers.*
Yea
Passed
12–0
Mar 5, 2020
Showing 3,721 to 3,730 of 3,765 votes